 In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primatesKiran Musunuru,
Alexandra C. Chadwick,
Taiji Mizoguchi,
Sara P. Garcia,
Jamie E. DeNizio,
Caroline W. Reiss,
Kui Wang,
Sowmya Iyer,
Chaitali Dutta,
Victoria Clendaniel,
Michael Amaonye,
Aaron Beach,
Kathleen Berth,
Souvik Biswas,
Maurine C. Braun,
Huei-Mei Chen,
Thomas V. Colace,
John D. Ganey,
Soumyashree A. Gangopadhyay,
Ryan Garrity,
Lisa N. Kasiewicz,
Jennifer Lavoie,
James A. Madsen,
Yuri Matsumoto,
Anne Marie Mazzola,
Yusuf S. Nasrullah,
Joseph Nneji,
Huilan Ren,
Athul Sanjeev,
Madeleine Shay,
Mary R. Stahley,
Steven H. Y. Fan,
Ying K. Tam,
Nicole M. Gaudelli,
Giuseppe Ciaramella,
Leslie E. Stolz,
Padma Malyala,
Christopher J. Cheng,
Kallanthottathil G. Rajeev,
Ellen Rohde,
Andrew M. Bellinger and
Sekar Kathiresan ()
Nature, 2021, vol. 593, issue 7859, 429-434 Abstract: Abstract Gene-editing technologies, which include the CRISPR–Cas nucleases1–3 and CRISPR base editors4,5, have the potential to permanently modify disease-causing genes in patients6. The demonstration of durable editing in target organs of nonhuman primates is a key step before in vivo administration of gene editors to patients in clinical trials. Here we demonstrate that CRISPR base editors that are delivered in vivo using lipid nanoparticles can efficiently and precisely modify disease-related genes in living cynomolgus monkeys (Macaca fascicularis). We observed a near-complete knockdown of PCSK9 in the liver after a single infusion of lipid nanoparticles, with concomitant reductions in blood levels of PCSK9 and low-density lipoprotein cholesterol of approximately 90% and about 60%, respectively; all of these changes remained stable for at least 8 months after a single-dose treatment. In addition to supporting a ‘once-and-done’ approach to the reduction of low-density lipoprotein cholesterol and the treatment of atherosclerotic cardiovascular disease (the leading cause of death worldwide7), our results provide a proof-of-concept for how CRISPR base editors can be productively applied to make precise single-nucleotide changes in therapeutic target genes in the liver, and potentially in other organs. Date: 2021 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:593:y:2021:i:7859:d:10.1038_s41586-021-03534-y Ordering information: This journal article can be ordered from DOI: 10.1038/s41586-021-03534-y Access Statistics for this article Nature is currently edited by Magdalena Skipper More articles in Nature from Nature |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.